AstraZeneca PLC (AZN)
The price, the headline numbers and the latest news, in one place.
AstraZeneca PLC (AZN) Stock Price, Analysis & Data
| Bid | 156.5 |
| Market Cap | 243B |
| Revenue (ttm) | 61.4B |
| Net Income (ttm) | 10.4B |
| 0.20 | |
| 6.54 | |
| 24 | |
| 13.82 | |
| P/B (ttm) | 4.84 |
| P/S (ttm) | 3.97 |
| Earnings Date | Oct 30, 2026 |
| Ask | 157.18 |
| Volume | 3,873,334 |
| Avg. Volume (20D) | 3,190,554 |
| Open | 158.31 |
| Previous Close | 160.04 |
| Day's Range | 156.74 - 159.13 |
| 52-Week Range | 145.80 - 212.71 |
| Analyst | Strong<br>Buy |
| Price Target | 215 (37%) |
| Dividends | $3.20 (2.04%) |
| Ex-Dividend Date | Aug 7, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormin...
Financial Performance
In 2025, AstraZeneca PLC's revenue was 58.74B, an increase of 8.63% compared to the previous year's 54.07B. Earnings were 10.23B, an increase of 45.34%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for AZN stock is "Strong Buy". The 12-month stock price forecast is 215, which is upside of 37% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $15.38B misses estimates by $0, with 6.41% YoY growth.
- EPS of 1.32 exceeds estimates by 0.07, with 5.60% YoY growth.
Analysts project revenue of ... Upgrade
